Financial Contrast: Wellgistics Health (NASDAQ:WGRX) versus Amylyx Pharmaceuticals (NASDAQ:AMLX)

Wellgistics Health (NASDAQ:WGRX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

Wellgistics Health has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Wellgistics Health and Amylyx Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wellgistics Health	1	0	0	0	1.00
Amylyx Pharmaceuticals	1	2	8	1	2.75

Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 72.67%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Wellgistics Health.

Earnings and Valuation

This table compares Wellgistics Health and Amylyx Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wellgistics Health	$23.34 million	0.47	-$101.28 million	($44.50)	-0.10
Amylyx Pharmaceuticals	$87.37 million	16.95	-$144.74 million	($1.50)	-8.88

Wellgistics Health has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 27.0% of Wellgistics Health shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Wellgistics Health and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wellgistics Health	-545.69%	-1,617.25%	-145.69%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Summary

Amylyx Pharmaceuticals beats Wellgistics Health on 12 of the 15 factors compared between the two stocks.

About Wellgistics Health

Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.